Home | Welcome to Contract Pharma   
Last Updated Saturday, August 2 2014
Print

Financial Report: Charles River Labs



Published May 1, 2014
Charles River Labs
 
1Q Revenues: $299.4 million (+3%)

1Q Earnings: $32.4 million (+26%)

Comments: RMS segment sales were $185.6 million in the quarter, up 2%, with growth in the Endotoxin and Microbial Detection (EMD) business. Preclinical Services (PCS) segment sales were $113.8 million, up 5% driven by continued demand from mid-tier biotechnology clients.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On